Truist Financial
IBB icon

Truist Financial’s iShares Biotechnology ETF IBB Stock Holding History

Truist Financial’s Portfolio IBB Stock Details IBB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$134M Sell
634,277
-43,076
-6% -$8.64M 0.16% 124
2026
Q2 		$129M Buy
677,353
+11,010
+2% +$1.89M 0.15% 126
2026
Q1 		$113M Buy
666,343
+24,320
+4% +$4.16M 0.15% 136
2025
Q4 		$108M Buy
642,023
+614,582
+2,240% +$100M 0.14% 137
2025
Q3 		$3.96M Sell
27,441
-920
-3% -$126K 0.01% 1002
2025
Q2 		$3.59M Sell
28,361
-17,325
-38% -$2.13M 0.01% 1007
2025
Q1 		$5.84M Sell
45,686
-7,201
-14% -$976K 0.01% 763
2024
Q4 		$6.99M Buy
52,887
+14,770
+39% +$2.08M 0.01% 691
2024
Q3 		$5.55M Buy
38,117
+2,758
+8% +$399K 0.01% 790
2024
Q2 		$4.85M Sell
35,359
-36,325
-51% -$4.85M 0.01% 873
2024
Q1 		$9.8M Buy
71,684
+44,682
+165% +$6.1M 0.01% 632
2023
Q4 		$3.67M Sell
27,002
-11,120
-29% -$1.36M 0.01% 982
2023
Q3 		$4.66M Sell
38,122
-27,146
-42% -$3.45M 0.01% 865
2023
Q2 		$8.29M Sell
65,268
-14,648
-18% -$1.9M 0.01% 650
2023
Q1 		$10.3M Buy
79,916
+5,709
+8% +$747K 0.02% 581
2022
Q4 		$9.7M Buy
74,207
+1,035
+1% +$134K 0.02% 579
2022
Q3 		$8.56M Buy
73,172
+12,890
+21% +$1.6M 0.02% 604
2022
Q2 		$7.09M Sell
60,282
-16,113
-21% -$1.91M 0.01% 691
2022
Q1 		$10M Sell
76,395
-24,503
-24% -$3.19M 0.02% 636
2021
Q4 		$15.4M Buy
100,898
+4,128
+4% +$639K 0.02% 509
2021
Q3 		$15.6M Buy
96,770
+2,494
+3% +$420K 0.03% 486
2021
Q2 		$15.4M Buy
94,276
+5,308
+6% +$818K 0.03% 501
2021
Q1 		$13.4M Buy
88,968
+197
+0.2% +$31.3K 0.02% 524
2020
Q4 		$13.4M Buy
88,771
+8,766
+11% +$1.25M 0.03% 517
2020
Q3 		$10.8M Buy
80,005
+8,004
+11% +$1.09M 0.02% 527
2020
Q2 		$9.8M Buy
72,001
+26,338
+58% +$3.36M 0.02% 533
2020
Q1 		$4.92M Sell
45,663
-23,994
-34% -$2.76M 0.01% 684
2019
Q4 		$8.39M Buy
+69,657
New +$7.77M 0.02% 621
2018
Q4 		– Sell
-2,571
Closed -$314K – 771
2018
Q3 		$314K Buy
2,571
+508
+25% +$59.8K 0.01% 673
2018
Q2 		$226K Buy
+2,063
New +$221K ﹤0.01% 716

Other funds holding IBB

WestEnd Advisors
WestEnd Advisors Charlotte, North Carolina $4.53B AUM 12.98% 1-Year Est. Return
Albion Financial Group
Albion Financial Group Salt Lake City, Utah $1.77B AUM 14.95% 1-Year Est. Return
Generali Investments CEE
Generali Investments CEE Prague, Czech Republic $2.11B AUM 18.35% 1-Year Est. Return
Appleton Partners
Appleton Partners Boston, Massachusetts $1.63B AUM 29.96% 1-Year Est. Return
MinichMacGregor Wealth Management
MinichMacGregor Wealth Management Saratoga Springs, New York $620M AUM 32.35% 1-Year Est. Return
Investment House LLC
Investment House LLC Redondo Beach, California $2.25B AUM 30.44% 1-Year Est. Return
AssetMark Inc
AssetMark Inc Concord, California $59.5B AUM 15.92% 1-Year Est. Return
Factory Mutual Insurance
Factory Mutual Insurance Waltham, Massachusetts $11.2B AUM 26.8% 1-Year Est. Return
NTV Asset Management
NTV Asset Management Charleston, West Virginia $1.08B AUM 23.94% 1-Year Est. Return
Cumberland Advisors
Cumberland Advisors Sarasota, Florida $280M AUM 17.5% 1-Year Est. Return

Truist Financial's IBB Position: Q3 2026 in Review

Truist Financial reduced its iShares Biotechnology ETF (IBB) stake by 6.4% in Q3 2026, selling an estimated $8.64M and leaving 634,277 shares worth $134M. The position accounts for 0.16% of the portfolio, ranked #124.

Truist Financial first reported a position in IBB in Q2 2018 and has held it in 30 quarters since. 434 funds tracked by Wall St. Rank hold IBB as of Q3 2026.

  • Truist Financial held 634,277 shares of iShares Biotechnology ETF worth $134M as of Q3 2026.
  • Truist Financial sold 43,076 iShares Biotechnology ETF shares in Q3 2026, an estimated $8.64M.
  • iShares Biotechnology ETF made up 0.16% of Truist Financial's portfolio in Q3 2026, its #124 holding.
  • Truist Financial first reported a position in iShares Biotechnology ETF in Q2 2018 and has held it in 30 quarters since.
  • 434 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q3 2026.

Based on Truist Financial's 13F filing for Q3 2026, filed 30 Oct 2026.